Vera Therapeutics, Inc. Contracts & Agreements

Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C., dated February 1, 2023 (Filed With SEC on February 2, 2023)

First Amendment to Loan and Security Agreement, by and between the Registrant and Oxford Finance, LLC, dated November 4, 2022 (Filed With SEC on November 9, 2022)

Amendment to License Agreement, dated September 9, 2022, by and between the Company and Novartis Pharma AG (Filed With SEC on September 9, 2022)

Description of Common Stock of the Registrant (Filed With SEC on March 28, 2022)

Form of Underwriting Agreement (Filed With SEC on February 7, 2022)

Loan and Security Agreement between the Registrant and Oxford Finance LLC, dated December 17, 2021 (Filed With SEC on February 7, 2022)

Asset Purchase Agreement between the Registrant and Amplyx Pharmaceuticals, Inc. dated December 16, 2021 (Filed With SEC on February 7, 2022)

License Agreement between Novartis International Pharmaceutical AG and Amplyx Pharmaceuticals, Inc. dated August 26, 2019 (Filed With SEC on February 7, 2022)

Amendment No. 1 to License Agreement between Novartis International Pharmaceutical AG and Amplyx Pharmaceuticals, Inc. dated September 24, 2019 (Filed With SEC on February 7, 2022)

Offer Letter, by and between the Company and Sean P. Grant, dated May 30, 2021 (Filed With SEC on July 14, 2021)

Form of Underwriting Agreement (Filed With SEC on May 10, 2021)

Form of Class A Common Stock Certificate (Filed With SEC on May 10, 2021)

Vera Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on May 10, 2021)

Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on May 10, 2021)

Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Vera Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on May 10, 2021)

Vera Therapeutics, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on May 10, 2021)

Vera Therapeutics, Inc. 2021 Non-Employee Director Compensation Policy (Filed With SEC on May 10, 2021)

Form of Indemnification Agreement by and between the Registrant and its directors and executive officers (Filed With SEC on May 10, 2021)

Amended and Restated Offer Letter by and between the Registrant and Marshall Fordyce, M.D., dated May 7, 2021 (Filed With SEC on May 10, 2021)

Amended and Restated Offer Letter by and between the Registrant and Joanne Curley, Ph.D., dated May 7, 2021 (Filed With SEC on May 10, 2021)

Amended and Restated Offer Letter by and between the Registrant and Celia Lin, M.D., dated May 7, 2021 (Filed With SEC on May 10, 2021)

Second Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated October 29, 2020 (Filed With SEC on April 23, 2021)

Vera Therapeutics, Inc. 2017 Equity Incentive Plan (Filed With SEC on April 23, 2021)

Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2017 Equity Incentive Plan (Filed With SEC on April 23, 2021)

Amended and Restated Offer Letter by and between the Registrant and Marshall Fordyce, M.D., dated December 22, 2020 (Filed With SEC on April 23, 2021)

Offer Letter by and between the Registrant and Joanne Curley, Ph.D., dated February 5, 2020 (Filed With SEC on April 23, 2021)

Amendment to Employment Agreement by and between the Registrant and Joanne Curley, Ph.D., dated September 3, 2020 (Filed With SEC on April 23, 2021)

Confidential Consulting Agreement by and between the Registrant and FLG Partners, LLC, dated March 15, 2020 (Filed With SEC on April 23, 2021)

Offer Letter by and between the Registrant and Allen Ebens, Ph.D., dated July 26, 2018 (Filed With SEC on April 23, 2021)

Separation Agreement by and between the Registrant and Allen Ebens, Ph.D., dated September 24, 2020 (Filed With SEC on April 23, 2021)

License Agreement by and between the Registrant and Ares Trading S.A., dated as of October 29, 2020 (Filed With SEC on April 23, 2021)